A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity
Abstract
:1. Introduction
2. Material and Methods
3. Results
3.1. Best-Corrected Visual Acuity (BCVA)
3.2. Spherical Equivalent (SE)
3.3. Myopia
3.4. Hypermetropia
3.5. Astigmatism
3.6. Anisometropia
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
Abbreviations
ROP | Retinopathy of prematurity |
VEGF | Vascular endothelial growth factor |
LPC | Laser photocoagulation |
BEAT | Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity |
SE | Spherical equivalent |
BCVA | Best corrected visual acuity |
RCT | Randomised control trial |
LogMAR | Logarithm of the Minimum Angle of Resolution |
IVB | Intravitreal bevacizumab |
IVR | Intravitreal ranibizumab |
IVI | Intravitreal injection |
GA | Gestational age |
BW | Birthweight |
B | Bevacizumab |
R | Ranibizumab |
A | Aflibercept |
VA | Visual acuity |
References
- Pertl, L.; Steinwender, G.; Mayer, C.; Hausberger, S.; Pöschl, E.M.; Wackernagel, W.; Wedrich, A.; El-Shabrawi, Y.; Haas, A. A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLoS ONE 2015, 10, e0129383. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Asano, S.; Inoue, T.; Kure, K.; Kitano, M.; Fujita, A.; Nagahara, M.; Asaoka, R.; Obata, R. Investigating the factors affecting myopia in retinopathy of prematurity after laser treatment. Int. J. Retin. Vitreous. 2023, 9, 27. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Mintz-Hittner, H.A.; Kennedy, K.A.; Chuang, A.Z. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl. J. Med. 2011, 364, 603–615. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Wang, A.T.; Dai, S. Preferred Treatment Patterns of Retinopathy of Prematurity: An International Survey. Pediatr. Rep. 2024, 16, 816–822. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ortiz-Seller, A.; Martorell, P.; Barranco, H.; Pascual-Camps, I.; Morcillo, E.; Ortiz, J.L. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis. Surv. Ophthalmol. 2024, 69, 585–605. [Google Scholar] [CrossRef]
- Avery, R.L.; Castellarin, A.A.; Steinle, N.C.; Dhoot, D.S.; Pieramici, D.J.; See, R.; Couvillion, S.; Nasir, M.A.; Rabena, M.D.; Maia, M.; et al. Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab. Retina 2017, 37, 1847–1858. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Geloneck, M.M.; Chuang, A.Z.; Clark, W.L.; Hunt, M.G.; Norman, A.A.; Packwood, E.A.; Tawansy, K.A.; Mintz-Hittner, H.A. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial. JAMA Ophthalmol. 2014, 132, 1327–1333. [Google Scholar] [CrossRef] [PubMed]
- Al-Balushi, N.A.-H.N. Ocular effects of intravitreal anti-vascular endothelial growth factor (ranibizumab) for retinopathy of prematurity attending tertiary hospital in Oman: Cross-sectional study. Oman Med. J. 2019, 34, 49. [Google Scholar]
- Arfat, M.Y. Comparison of Complications of Intravitreal Bevacizumab with Laser Photocoagulation for the Treatment of Retinopathy of Prematurity. Pak. J. Med. Health Sci. 2018 2018, 12, 1079–1081. [Google Scholar]
- Barnett, J.M.; Hubbard, G.B. Complications of retinopathy of prematurity treatment. Curr. Opin. Ophthalmol. 2021, 32, 475–481. [Google Scholar] [CrossRef]
- Bayramoglu, S.E.; Sayin, N. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: The importance of retinal vascularization. Int. Ophthalmol. 2022, 42, 3199–3210. [Google Scholar] [CrossRef] [PubMed]
- Bayramoglu, S.E.; Sayin, N. Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab. Indian J. Ophthalmol. 2022, 70, 3584–3590. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Chen, Y.H.; Chen, S.N.; Lien, R.I.; Shih, C.P.; Chao, A.N.; Chen, K.J.; Hwang, Y.-S.; Wang, N.-K.; Lee, K.-H.; Chuang, C.-C.; et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye 2014, 28, 1080–1086, quiz 1087. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Chen, S.N.; Lian, I.; Hwang, Y.C.; Chen, Y.H.; Chang, Y.C.; Lee, K.H.; Chuang, C.C.; Wu, W.C. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: Comparison between Ranibizumab and Bevacizumab. Retina 2015, 35, 667–674. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.C.; Chen, S.N.; Yang, B.C.; Lee, K.H.; Chuang, C.C.; Cheng, C.Y. Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age. J. Ophthalmol. 2018, 2018, 4565216. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Chen, Y.T.; Liu, L.; Lai, C.C.; Chen, K.J.; Hwang, Y.S.; Wu, W.C. Anatomical and Functional Results of Intravitreal Aflibercept Monotherapy for Type 1 Retinopathy of Prematurity: One-Year Outcomes. Retina 2020, 40, 2366–2372. [Google Scholar] [CrossRef] [PubMed]
- Cheng, H.; Cao, D.; Qian, J.; Gu, W.; Zheng, Z.; Ma, M. Refractive status and retinal morphology in children with a history of intravitreal ranibizumab for retinopathy of prematurity. Eur. J. Pediatr. 2023, 182, 3121–3128. [Google Scholar] [CrossRef] [PubMed]
- Chou, Y.-B.; Wang, A.-G.; Yang, H.-Y.; Chen, K.-J.; Yang, C.-S. Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: Systemic review and a 17-year longitudinal study. Graefe’s Arch. Clin. Exp. Ophthalmol. 2022, 260, 3809–3816. [Google Scholar] [CrossRef]
- Chow, S.C.; Lam, P.Y.; Lam, W.C.; Fung, N.S.K. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review. Eye 2022, 36, 1532–4155. [Google Scholar] [CrossRef] [PubMed]
- Crouch, E.R.; Kraker, R.T.; Wallace, D.K.; Holmes, J.M.; Repka, M.X.; Collinge, J.E.; Bremer, D.L.; Gray, M.E.; Smith, H.A.; Steinkuller, P.G.; et al. Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol. 2020, 138, 14–20. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Tiryaki Demir, S.; Keles Yesiltas, S.; Karapapak, M.; Betul Akbas Ozyurek, E.; Bulbul, A.; Sinan Uslu, H.; Guven, D. Evaluation of the Effect of Different Treatment Management on Refractive Outcomes in Severe Retinopathy of Prematurity. Sisli Etfal Hast. Tip. Bul. 2021, 55, 545–550. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Farvardin, M.; Kalantari, Z.; Talebnejad, M.; Alamolhoda, M.; Norouzpour, A. Long-term Visual and Refractive Outcomes of Argon Laser-treated Retinopathy of Prematurity. J. Ophthalmic Vis. Res. 2022, 17, 384–389. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Freedman, S.F.; Hercinovic, A.; Wallace, D.K.; Kraker, R.T.; Li, Z.; Bhatt, A.R.; Boente, C.S.; Crouch, E.R.; Hubbard, G.B.; Rogers, D.L.; et al. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology 2022, 129, 1120–1128. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Gundlach, B.S.; Kokhanov, A.; Altendahl, M.; Suh, S.Y.; Fung, S.; Demer, J.; Pineles, S.; Khitri, M.; Chu, A.; Tsui, I. Real-World Visual Outcomes of Laser and Anti-VEGF Treatments for Retinopathy of Prematurity. Am. J. Ophthalmol. 2022, 238, 86–96. [Google Scholar] [CrossRef] [PubMed]
- Harder, B.C.; von Baltz, S.; Schlichtenbrede, F.C.; Jonas, J.B. Early Refractive Outcome After Intravitreous Bevacizumab for Retinopathy of Prematurity. Arch. Ophthalmol. 2012, 130, 800–801. [Google Scholar] [CrossRef]
- Harder, B.C.; Schlichtenbrede, F.C.; von Baltz, S.; Jendritza, W.; Jendritza, B.; Jonas, J.B. Intravitreal bevacizumab for retinopathy of prematurity: Refractive error results. Am. J. Ophthalmol. 2013, 155, 1119–1124.e1. [Google Scholar] [CrossRef] [PubMed]
- Holt, D.; Hoppe, C.; Arnold, B.F.; Thinda, S.; Padmanabhan, S.; Oatts, J. Outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus 2022, 26, e23. [Google Scholar] [CrossRef]
- Hoppe, C.; Holt, D.G.; Arnold, B.F.; Thinda, S.; Padmanabhan, S.P.; Oatts, J.T. Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus 2022, 26, 305.e1–305.e6. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Hwang, E.S.; Kassem, I.S.; Allozi, R.; Kravets, S.; Al-Kirwi, K.Y.; Hallak, J.A.; Costakos, D.M. Association between myopia progression and quantity of laser treatment for retinopathy of prematurity. PLoS ONE 2022, 17, e0279898. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Isaac, M.; Mireskandari, K.; Fallaha, N.; Ospina, L.H.; Javidi, E.; Chorfi, S.; Superstein, R.; Hamel, P.; Tehrani, N.N. Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: A Canadian experience. Can. J. Ophthalmol. 2023, 58, 553–558. [Google Scholar] [CrossRef] [PubMed]
- Jeon, S.H.; Roh, Y.J. Ten-year outcomes after initial management with laser photocoagulation versus intravitreal bevacizumab injection in a pair of identical twins with aggressive posterior retinopathy of prematurity. Am. J. Ophthalmol. Case Rep. 2021, 22, 101097. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Jossy, A.; Kasturi, N.; Madhukar, S.P.; Babu, K.R.; Elias, S. Refractive outcomes following yttrium aluminum garnet laser (532 nm green laser) in severe retinopathy of prematurity. Oman J. Ophthalmol. 2022, 15, 331–336. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kang, H.G.; Choi, E.Y.; Byeon, S.H.; Kim, S.S.; Koh, H.J.; Lee, S.C.; Kim, M. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. Korean J. Ophthalmol. 2018, 32, 451–458. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Khan, A.; Haider, K. Refractive outcomes of patients treated for retinopathy of prematurity. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus 2022, 26, e24. [Google Scholar] [CrossRef]
- Kong, Q.; Ming, W.K.; Mi, X.S. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: A meta-analysis. BMJ Open. 2021, 11, e042384. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kuo, H.K.; Sun, I.T.; Chung, M.Y.; Chen, Y.H. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy. Ophthalmologica 2015, 234, 211–217. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.S.; See, L.C.; Chang, S.H.; Wang, N.K.; Hwang, Y.S.; Lai, C.C.; Chen, K.-J.; Wu, W.-C. Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment. Am. J. Ophthalmol. 2018, 192, 20–30. [Google Scholar] [CrossRef] [PubMed]
- Linghu, D.; Cheng, Y.; Zhu, X.; Deng, X.; Yin, H.; Jiang, Y.; Zhao, M.; Li, X.; Liang, J. Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1627 Eyes in China. Front. Med. 2022, 9, 911095. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Lu, X.; Zeng, X.; Chen, M.; Fan, Z.; Zheng, L.; Tian, Y.; Zhang, S.; He, J.C.; Zhang, G. Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection. Graefes Arch. Clin. Exp. Ophthalmol. 2022, 260, 3213–3219. [Google Scholar] [CrossRef] [PubMed]
- Marlow, N.; Stahl, A.; Lepore, D.; Fielder, A.; Reynolds, J.D.; Zhu, Q.; Weisberger, A.; Stiehl, D.P.; Fleck, B. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): Prospective follow-up of an open label, randomised controlled trial. Lancet Child. Adolesc. Health 2021, 5, 698–707. [Google Scholar] [CrossRef] [PubMed]
- Martínez-Castellanos, M.A.; Schwartz, S.; Hernández-Rojas, M.L.; Kon-Jara, V.A.; García-Aguirre, G.; Guerrero-Naranjo, J.L.; Chan, R.V.P.; Quiroz–Mercado, H. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina 2013, 33, 329–338. [Google Scholar] [CrossRef] [PubMed]
- Matsumura, S.; Matsumoto, T.; Katayama, Y.; Tomita, M.; Morikawa, H.; Itokawa, T.; Kawakami, M.; Hori, Y. Risk factors for early-onset high myopia after treatment for retinopathy of prematurity. Jpn. J. Ophthalmol. 2022, 66, 386–393. [Google Scholar] [CrossRef] [PubMed]
- Meng, Q.; Cheng, Y.; Wu, X.; Zhao, D.; Zhao, M.; Liang, J. Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity. Clin. Exp. Optom. 2020, 103, 495–500. [Google Scholar] [CrossRef] [PubMed]
- Mintz-Hittner, H.A.; Geloneck, M.M. Review of effects of anti-VEGF treatment on refractive error. Eye Brain 2016, 8, 135–140. [Google Scholar] [PubMed] [PubMed Central]
- Murakami, T.; Sugiura, Y.; Okamoto, F.; Okamoto, Y.; Kato, A.; Hoshi, S.; Nagafuji, M.; Miyazono, Y.; Oshika, T. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. 2021, 259, 2849–2855. [Google Scholar] [CrossRef]
- Murakami, T.; Okamoto, F.; Kinoshita, T.; Shinomiya, K.; Nishi, T.; Obata, S.; Ogura, S.; Nishihara, Y.; Tsukitome, H.; Jujo, T.; et al. Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: A multicentre study from J-CREST group. Eye 2023, 37, 3589–3595. [Google Scholar] [CrossRef]
- Pawar, N.; Somyashree, D.; Meenakshi, R.; Maheshwari, D.; Mohideen, S.; Sithiq Uduman, M. Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity. Indian J. Ophthalmol. 2023, 71, 2561–2568. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Popovic, M.M.; Nichani, P.; Muni, R.H.; Mireskandari, K.; Tehrani, N.N.; Kertes, P.J. Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3701 eyes. Surv. Ophthalmol. 2021, 66, 572–584. [Google Scholar] [CrossRef] [PubMed]
- Etezad Razavi, M.; Shoeibi, N.; Hassanzadeh, S.; Kianmehr, S.; Bakhtiari, E. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP). Strabismus 2020, 28, 49–54. [Google Scholar] [CrossRef] [PubMed]
- Sanjuán Riera, L.; Peralta Calvo, J.; Hernández Rivas, L.; Klein Burgos, C.; Roca Cabau, M. Functional results in children with retinopathy of prematurity treated with intravitreal bevacizumab. Arch. Soc. Esp. Oftalmol. 2023, 98, 386–390. [Google Scholar] [CrossRef] [PubMed]
- Rubino, S.; Quiram, P. Aggressive Posterior Retinopathy Of Prematurity: Functional Outcomes Following Intravitreal Bevacizumab. Investig. Ophthalmol. Vis. Sci. 2019, 60, 6539. [Google Scholar]
- Salman, A.G.; Said, A.M. Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Ophthalmic Res. 2015, 53, 15–20. [Google Scholar] [CrossRef] [PubMed]
- Hawn, K.; Shepherd, E.; Rossen, J.; Cohen, L.; Cohen, S.; Patel, A.; Meier, P.; Kimura, R.; Cohen, J. Long term visual and neurodevelopmental outcomes in ROP patients treated with laser photocoagulation versus intravitreal anti-VEGF therapy. Investig. Ophthalmol. Vis. Sci. 2020, 61, 2161. [Google Scholar]
- Simmons, M.; Wang, J.; Leffler, J.N.; Li, S.; Morale, S.E.; de la Cruz, A.; Birch, E.E. Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity. Transl. Vis. Sci. Technol. 2021, 10, 14. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Spiller, A.; Verkuil, L.; Forbes, B.; Yu, Y.; Ying, G.-S.; Binenbaum, G. Refractive outcomes after primary bevacizumab followed by laser versus primary laser alone for Retinopathy of Prematurity. Investig. Ophthalmol. Vis. Sci. 2022, 63, 4194–F0254. [Google Scholar]
- Süren, E.; Özkaya, D.; Çetinkaya, E.; Kalaycı, M.; Yiğit, K.; Kücük, M.F.; Erol, M.K. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment. Int. Ophthalmol. 2022, 42, 1905–1913. [Google Scholar] [CrossRef]
- Tan, Q.-Q.; Christiansen, S.P.; Wang, J.; Tsai, D.-C. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review. PLoS ONE 2019, 14, e0225643. [Google Scholar] [CrossRef]
- Tseng, C.C.; Chen, S.N.; Hwang, J.F.; Lin, C.J. Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab. J. Pediatr. Ophthalmol. Strabismus 2012, 49, e41–e43. [Google Scholar] [CrossRef] [PubMed]
- Tsiropoulos, G.N.; Seliniotaki, A.K.; Haidich, A.-B.; Ziakas, N.; Mataftsi, A. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: A systematic review. Int. Ophthalmol. 2023, 43, 1027–1062. [Google Scholar] [CrossRef]
- Wallace, D.K.; Hercinovic, A.; Freedman, S.F.; Crouch, E.R.; Bhatt, A.R.; Hartnett, M.E.; Yang, M.B.; Rogers, D.L.; Hutchinson, A.K.; Good, W.V.; et al. Two-year ocular and developmental outcomes of a phase 1 dosing study of bevacizumab for retinopathy of prematurity. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus 2022, 26, e11. [Google Scholar] [CrossRef]
- Wallace, D.K.; Hercinovic, A.; Freedman, S.F.; Crouch, E.R.; Bhatt, A.R.; Hartnett, M.E.; Yang, M.B.; Rogers, D.L.; Hutchinson, A.K.; Good, W.V.; et al. Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus 2023, 27, 10.e1–10.e8. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Wiecek, E.K.; Akula, J.; Vanderveen, D.; Mantagos, I.; Wu, C.; Curran, A.-L.; Fulton, A.B. Development of Anisometropic Amblyopia in Children treated for Type I Retinopathy of Prematurity. Investig. Ophthalmol. Vis. Sci. 2022, 63, 4193–F0253. [Google Scholar]
- Wiecek, E.; Akula, J.D.; Vanderveen, D.K.; Mantagos, I.S.; Wu, C.; Curran, A.L.; De Bruyn, H.; Peterson, B.; Fulton, A.B. Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation. Am. J. Ophthalmol. 2022, 240, 252–259. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Wu, P.Y.; Chen, H.C.; Hsueh, Y.J.; Chen, K.J.; Wang, N.K.; Liu, L.; Chen, Y.-P.; Hwang, Y.-S.; Lai, C.-C.; Wu, W.-C. Corneal topography in preterm children aged 2 years to 12 years with or without retinopathy of prematurity. Eye 2023, 37, 2565–2572. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kıran Yenice, E.; Kara, C. Development of myopia in laser-treated ROP infants: Prematurity or laser photocoagulation? Int. Ophthalmol. 2023, 43, 1453–1458. [Google Scholar] [CrossRef] [PubMed]
- Kıran Yenice, E.; Petriçli, İ.S.; Kara, C. One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity. Int. Ophthalmol. 2023, 43, 2197–2202. [Google Scholar] [CrossRef] [PubMed]
- Roohipoor, R.; Torabi, H.; Karkhaneh, R.; Riazi-Eafahani, M. Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity. J. Curr. Ophthalmol. 2019, 31, 61–65. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Sankar, M.J.; Sankar, J.; Mehta, M.; Bhat, V.; Srinivasan, R. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst. Rev. 2016, 2, Cd009734. [Google Scholar] [CrossRef] [PubMed]
- Rudnicka, A.R.; Kapetanakis, V.V.; Wathern, A.K.; Logan, N.S.; Gilmartin, B.; Whincup, P.H.; Cook, D.G.; Owen, C.G. Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: Implications for aetiology and early prevention. Br. J. Ophthalmol. 2016, 100, 882–890. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
Author/s | Title | Site Origin | Study Design | Cohort Size | Severity of ROP | Dose/Agent of Anti-VEGF/Other Intervention | Age at Follow-Up | Main Effect |
---|---|---|---|---|---|---|---|---|
Al-Balushi et al., 2019 [8] | Ocular effects of intravitreal anti-vascular endothelial growth factor (ranibizumab) for retinopathy of prematurity attending tertiary hospital in Oman: Cross-sectional study | Oman | Retrospective cross-sectional study | 166 eyes | Zone 1: 24.1%, Zone 2: 73.5%, Zone 3: 2.4%. Stage 2: 7.8%; Stage 3: 82.5%; Stage 4 AROP: 1.2%; 97.6% eyes had plus disease | ranibizumab | ~12 months | 6% myopia at 6 months; 7.2% myopia at 12 months |
Arfat et al., 2018 [9] | Comparison of complications of intravitreal bevacizumab with laser photocoagulation for the treatment of retinopathy of pre-maturity | Ireland | Comparative study | 70 infants: 35 IVB vs. 35 laser | - | bevacizumab | ~6 months | IVB: 5.7% high myopia + 2.85% very high myopia Laser: 17.1% high myopia IVB + 37.14% very high myopia |
Asano et al., 2023 [2] | Investigating the factors affecting myopia in retinopathy of prematurity after laser treatment | Japan | Retrospective study | 33 eyes | Type 1 ROP or prethreshold ROP | diode laser vs. non-ROP eyes | ~3 to 10 years | SE was significantly more myopic in the ROP group (p < 0.001) |
Barnett et al., 2021 [10] | Complications of retinopathy of prematurity treatment | - | Opinion piece | - | ROP in Zone 1 | - | - | 3.8% myopia post IVB vs. 51.4% laser |
Bayramoglu et al., 2022 [11] | Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization | Turkey | Retrospective case series | 181 infants | Type 1 ROP | bevacizumab | ~22.9 months | 5.1% high myopia 15.1% low myopia |
Bayramoglu et al., 2022 [12] | Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab | Turkey | Retrospective observational study | 171 eyes | Type 1 ROP and AROP | bevacizumab | ~18 months | 22.2% developed myopia after IVB. Retinal zone was correlated to development of myopia |
Chen et al., 2014 [13] | Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes | Taiwan (China) | Retrospective bicentre study | 64 eyes | - | bevacizumab | ~2 years | In IVB, only myopia was 47.5% and high myopia was 10%. When also treated with laser, myopia was 82.4% and high myopia was 29.4% |
Chen et al., 2015 [14] | Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab | Taiwan (China) | Retrospective case series | 72 eyes | Type 1 ROP | ranibizumab and bevacizumab | ~1 year | Higher chance of high myopia following bevacizumab |
Chen et al., 2018 [15] | Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age | Taiwan (China) | Retrospective case series | 62 eyes | Type 1 ROP | bevacizumab, ranibizumab | ~3 years | Higher incidence of high myopia in IVB |
Chen et al., 2020 [16] | Anatomical and functional results of intravitreal aflibercept monotherapy for type 1 retinopathy of prematurity: one-year outcomes | Taiwan (China) | Prospective cohort study | 17 eyes | Type 1 ROP | aflibercept | ~1 year | 20% had hyperopia, non-significant finding; 73.3% low myopia, 6.7% had high myopia; 12.5% anisometropia |
Cheng et al., 2023 [17] | Refractive status and retinal morphology in children with a history of intravitreal ranibizumab for retinopathy of prematurity | China | Prospective study | 204 infants | Type 1 ROP | ranibizumab | ~4–6 years | Nil myopic shift. Poorer BCVA compared to type 2 ROP children or nil ROP |
Chou et al., 2022 [18] | Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study | Taiwan (China) | Retrospective longitudinal study | 28 eyes | Threshold ROP | laser (810 nm diode laser) | ~17 years | All patients with ROP had myopia (average spherical equivalent of −6.35 D, ranges from −1.25 to −12.38 D), and 12 eyes (43%) were highly myopic (spherical equivalent < −6.0 D). Threshold ROP eyes exhibited significantly poorer visual acuity (p < 0.001), greater cylinder refractive error (p < 0.001), higher corneal astigmatism (p < 0.001), and flatter horizontal corneal curvature (p = 0.01) compared with age-matched controls |
Chow et al., 2022 [19] | The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review | - | Review | - | - | anti-VEGF | - | Low chance of high myopia compared to laser |
Crouch et al., 2020 [20] | Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity | USA | Prospective cohort study | 46 eyes | Type 1 ROP | 0.625 mg–0.031 mg bevacizumab | ~12 months | 14% high myopia 2% high hyperopia 11% anisometropia |
Demir et al., 2021 [21] | Evaluation of the effect of different treatment management on refractive outcomes in severe retinopathy of prematurity | Turkey | Retrospective, non-randomised, cross-sectional, observational clinical study | 160 eyes: 38 IVB + 24 laser + 16 both + 44 spontaneous regression + 38 normal | Type 1 ROP or APROP | IVB or laser or both | ~18 months to 5 years | Although the mean spherical power and SE in the IVB group were lower than in the LPC group (p = 0.019 and 0.013, respectively), there was no significant difference between the IVB group and the IVB + LPC group (p = 0.541 and 0.804, respectively). In terms of mean cylindrical power and prevalence of myopia and anisometropia, there was no significant difference between the treatment groups (p > 0.05) |
Farvardin et al., 2022 [22] | Long-term Visual and Refractive Outcomes of Argon Laser-treated Retinopathy of Prematurity | Iran | Case–control study | 24 laser-treated eyes + 186 spontaneously regressed ROP eyes + 74 premature eyes of non-ROP + 286 normal eyes | Type 1 ROP | laser | ~6–7 years | Anisometropia (≥1.5 diopters) was diagnosed with a higher rate in the treated cases (p = 0.03) |
Freedman et al., 2022 [23] | Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes | USA | Masked multicentre dose de-escalation study | 113 eyes | Type 1 ROP | 2 x low dose (0.25–0.031 mg) OR very low dose (0.016–0.002 mg) bevacizumab | 12 months | Median myopia was mild (−0.31 D) |
Gundlach et al., 2022 [24] | Real-World Visual Outcomes of Laser and Anti-VEGF Treatments for Retinopathy of Prematurity | USA | Retrospective interventional case series | 350 eyes | Type 1 and type 2 ROP | 0.625 mg bevacizumab or 0.25 mg ranibizumab | ~9 years | No difference in myopia between anti-VEGF and laser |
Harder et al., 2012 [25] | Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity | Germany | Prospective study | 12 eyes IVB and 20 eyes laser | Zone 1 or zone 2 ROP | 0.375 mg bevacizumab | ~10 months | Less myopia in IVB compared to laser. Nil difference in astigmatism |
Harder et al., 2013 [26] | Intravitreal bevacizumab for retinopathy of prematurity: refractive error results | Germany | Retrospective non-randomized interventional comparative study | 23 IVB eyes and 26 laser eyes | Zone 1 or zone 2 ROP | 0.375 mg or 0.625 mg bevacizumab | ~1 year | Less myopia in IVB (−1.04 D) compared to laser (−4.41 D) Moderate myopia: 17% in IVB vs. 54% laser High myopia: 9% IVB vs. 42% laser Astigmatism was significantly lower in IVB |
Holt et al., 2022 [27] | Outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity | USA | Retrospective case series | 70 eyes | Type 1 ROP | ranibizumab and laser | ~2 years | 7% high myopia, 33% low myopia, 13% low hyperopia, and 9% high hyperopia |
Hoppe et al., 2022 [28] | Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity | USA | Retrospective observational study | 68 eyes | Type 1 ROP | 0.25 mg ranibizumab and delayed laser | ~2.7 years | SE: −0.13 D and high myopia (7%) |
Hwang. et al., 2022 [29] | Association between myopia progression and quantity of laser treatment for retinopathy of prematurity | USA | Retrospective study | 153 eyes | Treatable ROP | laser photocoagulation 810 nm indirect laser with a 28 D lens to apply near-confluent spots | ~37 ± 29 months | Eyes that received more laser spots had significantly greater change in refractive error over time (0.30 D more myopia per year per 1000 spots) |
Isaac et al., 2022 [30] | Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: a Canadian experience | Canada | Retrospective observational study | 101 eyes | 24% zone 1 ROP + 77% zone 2 ROP | 0.625 mg bevacizumab | ~5 years | Myopia incidence 17.8% High myopia 9.9% Very high myopia 12.9% Hyperopia 16.8% |
Jeon et al., 2021 [31] | Ten-year outcomes after initial management with laser photocoagulation versus intravitreal bevacizumab injection in a pair of identical twins with aggressive posterior retinopathy of prematurity | South Korea | Case report | 2 eyes | AP-ROP | 2 × 0.313 mg bevacizumab | ~10 years | BCVA: 20/20 and 20/50 in IVB BCVA: 20/50 and counting fingers in laser + IVB Severe myopia + astigmatism in laser + IVB |
Jossy et al., 2022 [32] | Refractive outcomes following yttrium aluminum garnet laser (532 nm green laser) in severe retinopathy of prematurity | India | Cross-sectional comparative study | 51 infants in each group | Treatable ROP as per ETROP | frequency-doubled neodymium-doped yttrium aluminium garnet (Nd-YAG) laser 532 nm (green laser) vs. spontaneous regression | ~1–2 years | Spherical equivalent (SE) ranged from −8.25 D to +5.50 D in Group 1 and −1.00 D to +4.00 D in Group 2. Group 1 had an incidence of 23.5% of myopia and 33.4% of astigmatism, which was significantly more than Group 2. The linear regression model predicted a decrease in SE of 0.658 D if the number of laser spots increased by 1000 |
Kang et al., 2018 [33] | Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes | South Korea | Retrospective comparative study | 153 eyes | - | bevacizumab, ranibizumab | ~30 months | No difference in SE |
Khan et al., 2022 [34] | Refractive outcomes of patients treated for retinopathy of prematurity | USA | Retrospective study | 133 infants | - | bevacizumab | ~3–4 years | No difference in myopia incidence between IVB, laser or both |
Kong et al., 2021 [35] | Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis | - | Systematic review and meta-analysis | 1850 eyes: 914 eyes with anti-VEGF and 936 eyes with laser | - | anti-VEGF vs. LPC | 9 months to 5 years | Less incidence of myopia in anti-vegf treatment than laser |
Kuo et al., 2015 [36] | Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy | Taiwan (China) | Retrospective observational study | 54 eyes, of which 15 had IVB | Type 1 and type 2 ROP | bevacizumab | ~3 years | SE: −1.71 ± 1.27 D laser vs −1.53 ± 2.20 D in IVB. No difference in myopia cases between IVB and laser |
Lee et al., 2018 [37] | Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment | Taiwan (China) | Comparative interventional case series | 80 eyes | Type 1 ROP | 0.625 mg bevacizumab | ~4.9 years | Less myopia in IVB- than laser-treated children. Same BCVA in both cohorts |
Linghu et al., 2022 [38] | Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1627 eyes in China | China | Retrospective non-randomised comparative study | 212 eyes | Type 1 ROP or APROP: Group 1: A-ROP or zone 1, Group 2: zone 2 stage 2 or stage 3 ROP with plus disease | laser (810 nm diode laser) or anti-VEGF (bevacizumab, ranibizumab, conbercept) | ~1 year | Refractive data from eyes of regressed ROP patients after 1 year of anti-VEGF injection or laser therapy were significantly different. In anti-VEGF, mean astigmatism was 0.19 ± 1.51 D, and the mean spherical equivalent was 1.8 ± 1.99 D. In laser, mean astigmatism was −0.37 ± 1.62. Statistical differences were found between these two groups. Spherical equivalents were significantly higher in eyes treated with laser than in eyes treated with anti-VEGF agents (p = 0.06, p < 0.001, respectively). No difference was found in the power of astigmatism (p = 0.201) |
Lu et al., 2022 [39] | Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection | China | Case–control study | 27 eyes with IVB and 28 eyes laser | Zone 2 stage 3 ROP | ranibizumab | ~5 years | SE: −2.43 ± 3.56 in laser vs −0.53 ± 3.12 in IVR BCVA: log MAR, 0.17 ± 0.14 in laser vs. 0.21 ± 0.18 in IVR |
Marlow et al., 2021 [40] | 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial | USA, Austria, Belgium, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hungary, India, Italy, Japan, Lithuania, Malaysia, Romania, Russia, Saudi Arabia, Slovakia, Taiwan (China), Turkey, UK | Prospective study | 180 infants | - | 0.2 mg ranibizumab | ~2 years | High myopia: 5% IVR vs. 20% laser |
Martinez-Castellanos et al., 2013 [41] | Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up | Mexico | Prospective, interventional, noncomparative case study | 18 eyes | Type 1 ROP | bevacizumab | ~5 years | VA: 20/25 + low myopia in 12/18 cases (−3.2 D) |
Matsumura et al., 2022 [42] | Risk factors for early-onset high myopia after treatment for retinopathy of prematurity | Japan | Retrospective observational study | 178 eyes | Type 1 ROP | laser: 180–380 mW for 300 ms | ~3 years | Prevalence of myopia and high myopia was significantly higher in the treated group (59.7% and 17.9%, respectively) than in the untreated group (19.7% and 0%, respectively) (p < 0.001). The frequency of high myopia increased steeply in infants weighing less than 1000 g at birth |
Meng et al., 2020 [43] | Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity | China | Retrospective observational study | 186 eyes | Type 1 ROP | 0.25 mg repeated ranibizumab injections | ~2 years | 37.5% myopia and 3.4% high myopia |
Mintz-Hittner et al., 2016 [44] | Review of effects of anti-VEGF treatment on refractive error | - | Review | 466 eyes | - | bevacizumab, ranibizumab, or aflibercept | - | Mean SE: +0.75 D to −3.57 D High myopia from 0 to 35% |
Murakami et al., 2021 [45] | Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity | Japan | Prospective observational study | 52 eyes: 28 eyes laser + 24 eyes IVB | - | bevacizumab | ~5 years | Zone 1 low stage treated with IVB more than laser. No difference in BCVA and SE. More myopia in laser |
Murakami et al., 2023 [46] | Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: a multicentre study from J-CREST group | Japan | Multicentre retrospective study | 264 eyes: 187 eyes laser + 77 eyes IVI | Type 1 ROP/ A-ROP | - | ~4 years | Better BCVA in IVI vs. laser. Higher SE in IVI than laser |
Pawar et al., 2023 [47] | Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity | India | Retrospective study | 134 eyes | Type 1 ROP | bevacizumab or bevacizumab + laser | ~1 year | Major refractive error was myopia. Low-to-moderate myopia was seen in 75 eyes (56%), high myopia in 18 eyes (13.4%), emmetropia in 18.7%, and hypermetropia in 11.9% of eyes. In the control group, the majority of eyes (91.8%) had emmetropia. There was no statistically significant difference in refractive outcomes in children treated with additional laser therapy when compared to children who received only IVB therapy. The prevalence of low-to-moderate myopia was more than that of high myopia in participants with zone 1 and zone 2 ROP before treatment |
Popovic et al., 2021 [48] | Intravitreal Anti-Vascular Endothelial Growth Factor Injection versus Laser Photocoagulation for Retinopathy of Prematurity: A Meta-Analysis of 3701 Eyes | - | Systematic review + metanalysis | 3701 eyes: 1289 eyes IVI and 2412 eyes laser | - | - | - | Astigmatism was significantly lower following IVI compared to laser |
Razavi et al., 2020 [49] | Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP) | Iran | Prospective cohort study | 87 infants: 38 IVB vs. 49 no tx | - | 0.625 mg bevacizumab | ~1 year | Similar myopia and anisometropia rates in IVB vs. non-treated patients. Non-significant |
Riera et al., 2023 [50] | Functional results in children with retinopathy of prematurity treated with intravitreal bevacizumab | Spain | Retrospective study | 76 eyes | High-risk type 1 ROP | 0.625 mg bevacizumab | ~3 years | Median spherical equivalent at last examination was +0.94 (RIQ: −0.25, 1.88). Two eyes were emmetropic. Fifteen eyes (20%) had myopia. Fifty-seven eyes (77%) had hypermetropria. Seventy-two eyes (97%) had some degree of astigmatism |
Rubino et al., 2019 [51] | Aggressive posterior retinopathy of prematurity: Functional outcomes following intravitreal bevacizumab | USA | Retrospective study | 43 eyes: 35 eyes received subsequent laser | AP-ROP | bevacizumab and laser | ~4 years | 55% were myopic + 41% hyperopic |
Salman et al., 2015 [52] | Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity | Egypt | Prospective non-randomized interventional case series study | 26 eyes | High-risk pre-threshold type 1 ROP | 1 mg aflibercept | ~1 year | On average, mild hyperopia at 0.75 D (range: −9.5 to +4) |
Hawn et al., 2020 [53] | Long term visual and neurodevelopmental outcomes in ROP patients treated with laser photocoagulation versus intravitreal anti-VEGF therapy | USA | Retrospective observational study | 24 infants: 14 laser + 10 IVB/R | - | bevacizumab or ranibizumab | 2–12 years | Laser treatment led to more myopia (−8 D) than IVB/R treatment (−2 D) |
Simmons et al., 2021 [54] | Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity | USA | Prospective cohort study | IVB: 22 infants + laser: 26 infants | Type 1 ROP: stage 3+ or posterior ROP in zone 1 or zone 2 | 0.625 mg bevacizumab | ~3.5 years | Myopia: 82.7% laser vs. 47.7% IVB SE: −8.0 D ± 5.8 D laser vs. −2.3 D ± 4.2 D IVB Rate of SE change: −5 D/year in laser vs. −3.5 D/year in IVB Low anisometropia in IVB vs. laser VA same in both cohorts |
Spiller et al., 2022 [55] | Refractive outcomes after primary bevacizumab followed by laser versus primary laser alone for Retinopathy of Prematurity. | USA | Retrospective cohort analysis | 28 eyes had IVB and laser vs. 297 eyes had laser only | Type 1 ROP | bevacizumab and laser | ~19 months | Similar incidence of myopia and high myopia in laser +IVB vs. laser alone |
Suren et al., 2022 [56] | Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment. | Turkey | Retrospective study | 187 eyes: 53 eyes B, 77 eyes R, 56 eyes A | - | bevacizumab, ranibizumab, aflibercept | ~3 years | Myopic shift for IVB |
Tan et al., 2019 [57] | Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review. | - | Systematic review and meta-analysis | 272 eyes IVB and 247 eyes laser | Type 1 ROP | bevacizumab | - | Low prevalence of myopia, high myopia, and astigmatism in IVB treatment vs. laser |
Tseng et al., 2012 [58] | Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab. | Taiwan (China) | Case report | 3 infants | Stage 2–3 ROP | bevacizumab | - | One child developed myopia; the other did not |
Tsiropoulos et al., 2023 [59] | Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review. | - | Systematic review | - | Treatment requiring ROP | bevacizumab, ranibizumab, aflibercept, pegaptanib, conbercept | - | More myopia in laser vs. IVI |
Wallace et al., 2022 [60] | Two-year ocular and developmental outcomes of a phase 1 dosing study of bevacizumab for retinopathy of prematurity. | USA | Multicentre, dose de-escalation study | 134 eyes | Type 1 ROP | 0.002–0.25 mg bevacizumab | ~2 years | 16% high myopia + 17% anisometropia |
Wallace et al., 2023 [61] | Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity. | USA | Multicentre, phase 1 dose de-escalation study | 120 infants | Type 1 ROP | 0.002–0.25 mg bevacizumab | ~2 years | 21% high myopia |
Wiecek et al., 2022 [62] | Development of Anisometropic Amblyopia in Children treated for Type I Retinopathy of Prematurity. | USA | Retrospective study | 40 infants IVB vs. 48 infants laser | - | bevacizumab | ~3.2 years | High incidence of anisometropia post IVB + laser |
Wiecek et al., 2022 [63] | Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation | USA | Retrospective observational study | 88 infants: 40 eyes IVB, 90 eyes laser, 36 eyes both | 13.% had zone 1 ROP + 36.3% had zone 2 ROP | 0.5 mg bevacizumab | ~3 years | No myopic progression |
Wu et al., 2023 [64] | Corneal topography in preterm children aged 2 years to 12 years with or without retinopathy of prematurity | Taiwan (China) | Prospective longitudinal cohort study | 131 infants | Type 1 ROP | - | ~7 years | Higher incidence of astigmatism in laser treatment vs. anti-VEGF |
Yenice et al., 2023 [65] | Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation? | Turkey | Retrospective study | 157 eyes | Type 1 ROP | laser (810 nm transpupillary diode laser) | ~1 year | No significant association was found between GA, BW, and ROP zone and SE value, while the number of laser spots (ß = −0.27 ± 0.00 D, p = 0.00) and stage 3 ROP (ß = −0.29 ± 0.37 D, p = 0.00) were significantly associated with SE value. In multivariable linear regression analysis, significant associations were found between the number of laser spots, stage 3 ROP, and SE value (ß = −0.25 ± 0.00 D, p = 0.01 for number of laser spots, ß = −0.28 ± 0.36 D, p = 0.00 for stage 3 ROP) |
Yenice et al., 2022 [66] | One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity | Turkey | Retrospective cohort study | 86 eyes | Type 1 ROP | 0.625 mg bevacizumab | ~12 months | SE: 0.8 ± 1.7 D in IVB vs. − 0.5 ± 2.0 D laser. SE was lower in zone 1 ROP than in zone 2 for IVB-treated children. There was lower incidence of low + high myopia in IVB than laser. There were more cases of mild hypermetropia in IVB than laser |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wang, A.T.; Gupta, I.; Dai, S. A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity. J. Clin. Med. 2025, 14, 810. https://doi.org/10.3390/jcm14030810
Wang AT, Gupta I, Dai S. A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity. Journal of Clinical Medicine. 2025; 14(3):810. https://doi.org/10.3390/jcm14030810
Chicago/Turabian StyleWang, Amy T., Isha Gupta, and Shuan Dai. 2025. "A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity" Journal of Clinical Medicine 14, no. 3: 810. https://doi.org/10.3390/jcm14030810
APA StyleWang, A. T., Gupta, I., & Dai, S. (2025). A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity. Journal of Clinical Medicine, 14(3), 810. https://doi.org/10.3390/jcm14030810